232 related articles for article (PubMed ID: 8397367)
1. Co-localization of the tumor-suppressor protein p53 and human papillomavirus E6 protein in human cervical carcinoma cell lines.
Liang XH; Volkmann M; Klein R; Herman B; Lockett SJ
Oncogene; 1993 Oct; 8(10):2645-52. PubMed ID: 8397367
[TBL] [Abstract][Full Text] [Related]
2. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.
Pillai MR; Halabi S; McKalip A; Jayaprakash PG; Rajalekshmi TN; Nair MK; Herman B
Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297
[TBL] [Abstract][Full Text] [Related]
3. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53.
Liang XH; Mungal S; Ayscue A; Meissner JD; Wodnicki P; Hockenbery D; Lockett S; Herman B
J Cell Biochem; 1995 Mar; 57(3):509-21. PubMed ID: 7768985
[TBL] [Abstract][Full Text] [Related]
5. In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma.
Madrigal M; Janicek MF; Sevin BU; Perras J; Estape R; Peñalver M; Averette HE
Gynecol Oncol; 1997 Jan; 64(1):18-25. PubMed ID: 8995542
[TBL] [Abstract][Full Text] [Related]
6. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand.
Koivusalo R; Krausz E; Ruotsalainen P; Helenius H; Hietanen S
Cancer Res; 2002 Dec; 62(24):7364-71. PubMed ID: 12499281
[TBL] [Abstract][Full Text] [Related]
7. High-risk HPV E6 oncoproteins assemble into large oligomers that allow localization of endogenous species in prototypic HPV-transformed cell lines.
García-Alai MM; Dantur KI; Smal C; Pietrasanta L; de Prat-Gay G
Biochemistry; 2007 Jan; 46(2):341-9. PubMed ID: 17209544
[TBL] [Abstract][Full Text] [Related]
8. Recombinant adenovirus-p53 gene transfer and cell-specific growth suppression of human cervical cancer cells in vitro and in vivo.
Ahn WS; Bae SM; Lee KH; Lee JM; Namkoong SE; Chun HJ; Kim CK; Kim YW
Gynecol Oncol; 2004 Feb; 92(2):611-21. PubMed ID: 14766255
[TBL] [Abstract][Full Text] [Related]
9. Neocarzinostatin induces an effective p53-dependent response in human papillomavirus-positive cervical cancer cells.
Bañuelos A; Reyes E; Ocadiz R; Alvarez E; Moreno M; Monroy A; Gariglio P
J Pharmacol Exp Ther; 2003 Aug; 306(2):671-80. PubMed ID: 12750435
[TBL] [Abstract][Full Text] [Related]
10. Induction of the p53-target gene GADD45 in HPV-positive cancer cells.
Butz K; Whitaker N; Denk C; Ullmann A; Geisen C; Hoppe-Seyler F
Oncogene; 1999 Apr; 18(14):2381-6. PubMed ID: 10327059
[TBL] [Abstract][Full Text] [Related]
11. Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses.
Howley PM; Münger K; Romanczuk H; Scheffner M; Huibregtse JM
Princess Takamatsu Symp; 1991; 22():239-48. PubMed ID: 1668886
[TBL] [Abstract][Full Text] [Related]
12. p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene.
Spitkovsky D; Aengeneyndt F; Braspenning J; von Knebel Doeberitz M
Oncogene; 1996 Sep; 13(5):1027-35. PubMed ID: 8806692
[TBL] [Abstract][Full Text] [Related]
13. The state of p53 in primary human cervical carcinomas and its effects in human papillomavirus-immortalized human cervical cells.
Chen TM; Chen CA; Hsieh CY; Chang DY; Chen YH; Defendi V
Oncogene; 1993 Jun; 8(6):1511-8. PubMed ID: 8389030
[TBL] [Abstract][Full Text] [Related]
14. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.
López-Ocejo O; Viloria-Petit A; Bequet-Romero M; Mukhopadhyay D; Rak J; Kerbel RS
Oncogene; 2000 Sep; 19(40):4611-20. PubMed ID: 11030150
[TBL] [Abstract][Full Text] [Related]
15. Role of p53 in antioxidant defense of HPV-positive cervical carcinoma cells following H2O2 exposure.
Ding B; Chi SG; Kim SH; Kang S; Cho JH; Kim DS; Cho NH
J Cell Sci; 2007 Jul; 120(Pt 13):2284-94. PubMed ID: 17567683
[TBL] [Abstract][Full Text] [Related]
16. DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6.
Gu Z; Pim D; Labrecque S; Banks L; Matlashewski G
Oncogene; 1994 Feb; 9(2):629-33. PubMed ID: 8290274
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the p53 gene in human uterine carcinoma cell lines.
Yaginuma Y; Westphal H
Cancer Res; 1991 Dec; 51(24):6506-9. PubMed ID: 1660340
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro.
Nakagawa S; Watanabe S; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
Virology; 1995 Oct; 212(2):535-42. PubMed ID: 7571423
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor (VEGF) up-regulates epidermal growth factor receptor (EGF-R) in cervical cancer in vitro: this action is mediated through HPV-E6 in HPV-positive cancers.
Mathur RS; Mathur SP
Gynecol Oncol; 2005 Apr; 97(1):206-13. PubMed ID: 15790460
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.
Mantovani F; Banks L
Oncogene; 1999 Jun; 18(22):3309-15. PubMed ID: 10362351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
